Celldex Therapeutics (NASDAQ:CLDX) Reaches New 12-Month Low Following Analyst Downgrade
Celldex Therapeutics, Inc. (NASDAQ:CLDX – Get Free Report) shares hit a new 52-week low on Monday after The Goldman Sachs Group lowered their price target on the stock from $42.00 to $36.00. The Goldman Sachs Group currently has a neutral rating on the stock. Celldex Therapeutics traded as low as $19.66 and last traded at […]
Celldex Therapeutics, Inc. (NASDAQ:CLDX – Get Free Report) shares hit a new 52-week low on Monday after The Goldman Sachs Group lowered their price target on the stock from $42.00 to $36.00. The Goldman Sachs Group currently has a neutral rating on the stock. Celldex Therapeutics traded as low as $19.66 and last traded at […]
